VBI Vaccines Inc. (VBIV)

VBI Vaccines Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	9.41	8.68	1.08	0.63	1.06	2.22
Revenue Growth (YoY)	553.09%	702.40%	71.47%	-40.53%	-52.23%	-33.80%
Cost of Revenue	11.68	12.51	11.28	10.77	9.17	7.9
Gross Profit	-2.26	-3.83	-10.19	-10.14	-8.11	-5.68
Selling, General & Admin	36.53	42.14	56.12	38.34	20.65	14.09
Research & Development	8.76	9.34	15.51	19.56	14.86	26.33
Other Operating Expenses	24.6	24.6	0	0	0	6.29
Operating Expenses	69.89	76.09	71.63	57.89	35.51	46.72
Operating Income	-72.16	-79.91	-81.82	-68.03	-43.62	-52.4
Interest Expense / Income	6.79	6.4	4.01	4.73	2.71	2.2
Other Expense / Income	4.04	6.52	27.48	-3.01	-0.1	0.22
Pretax Income	-82.99	-92.84	-113.3	-69.75	-46.23	-54.81
Net Income	-82.99	-92.84	-113.3	-69.75	-46.23	-54.81
Preferred Dividends	1.01	1.01	0	0	0	0
Net Income Common	-83.99	-93.84	-113.3	-69.75	-46.23	-54.81
Shares Outstanding (Basic)	25	16	9	8	7	4
Shares Outstanding (Diluted)	25	16	9	8	7	4
Shares Change	185.59%	80.90%	1.30%	16.80%	82.73%	81.95%
EPS (Basic)	-5.65	-6.03	-13.16	-8.10	-6.30	-13.80
EPS (Diluted)	-5.65	-6.03	-13.16	-8.10	-6.30	-13.80
Free Cash Flow	-51.48	-61.75	-78.04	-41.9	-48.05	-52.39
Free Cash Flow Per Share	-2.09	-3.96	-9.06	-4.93	-6.60	-13.16
Gross Margin	-24.06%	-44.06%	-942.14%	-1606.81%	-764.09%	-255.88%
Operating Margin	-766.73%	-920.42%	-7561.92%	-10781.62%	-4110.93%	-2359.25%
Profit Margin	-892.47%	-1080.87%	-10471.63%	-11054.36%	-4357.21%	-2467.94%
Free Cash Flow Margin	-547.03%	-711.24%	-7212.48%	-6640.73%	-4528.75%	-2358.62%
EBITDA	-74.22	-84.45	-107.24	-63.19	-41.87	-51.41
EBITDA Margin	-788.65%	-972.64%	-9910.81%	-10013.63%	-3946.28%	-2314.86%
Depreciation & Amortization	1.98	1.99	2.06	1.84	1.65	1.2
EBIT	-76.2	-86.44	-109.3	-65.02	-43.52	-52.62
EBIT Margin	-809.64%	-995.57%	-10101.29%	-10304.44%	-4101.98%	-2369.07%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).